Get started
Author

Yang Shi

ORCID: 0000-0002-6713-9678
Observed ORCID: 0000-0002-6713-9678
OpenAlex ID: A5101935425
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study
2025 · Jennifer R. Brown, Jessica Li, et al. · Blood Advances · 19
TAGET: a toolkit for analyzing full-length transcripts from long-read sequencing
2023 · Yuchao Xia, Zijie Jin, et al. · Nature Communications · 15
PDF
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al. · Clinical Cancer Research · 3
PDF
Data from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S4 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S6 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S5 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S3 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Material S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Tables S1-S15 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Material S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)
2025 · Jessica Li, Yang Shi, et al. · Blood
Works count: 14
Citation count: 37
H-index: 3
I10-index: 2
Year
Topic
Type